ORAL LACOSAMIDE AND ORAL TOPIRAMATE IN PREVENTING MIGRAINE ATTACKS
Not Applicable
Recruiting
- Conditions
- Chronic migraine.Migraine
- Registration Number
- IRCT20230809059091N1
- Lead Sponsor
- Combined Military Hospital Rahim Yar Khan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
ALL PATIENTS AGED 18-30 YEARS DIAGNOSED WITH MIGRAINE ACCORDING TO THE ICHD 3 CRITERIA
PATIENTS WITH CHRONIC MIGRAINE AS HEADACHE OCCURRING ON 15 OR MORE DAYS PER MONTH FOR MORE THAN THREE MONTHS, WHERE AT LEAST 8 OF THOSE HEADACHE DAYS HAVE MIGRAINE FEATURES
Exclusion Criteria
PATIENTS WITH KNOWN HYPERTENSION, DIABETES OR ADVANCED CARDIAC OR RESPIRATORY DISEASE
PATIENTS WITH ALLERGY TO EITHER LACOSAMIDE OR TOPIRAMATE
PATIENTS WITH AN ACUTE EPISODE OF MIGRAINE IN THE LAST ONE WEEK
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of migraine attacks and improvement in quality of life. Timepoint: Three months post-intervention. Method of measurement: Standardized Chronic headache quality of life questionnaire.
- Secondary Outcome Measures
Name Time Method